Cellectar Biosciences, Inc. — Q1 2023 Form 10-Q
Business context and period. The company is a clinical-stage biopharmaceutical developer focused on cancer treatments using its phospholipid drug conjugate (PDC) platform. This unaudited report covers the three months ended March 31, 2023; comparisons are with Q1 2022 unless noted. Cellectar reported no revenue.
Financial performance and position
- Expenses and loss: R&D expense was $6.65 million, up 71%; general and administrative expense was $2.05 million, down 9%. Total costs and expenses were $8.71 million. Net loss was $8.58 million versus $6.14 million, while basic and diluted loss per share was $0.76 versus $1.00.
- Cash flow: Operating cash use was $7.18 million, compared with $5.04 million in Q1 2022. Cash and cash equivalents fell from $19.87 million at year-end 2022 to $12.68 million at March 31, 2023. There were no investing cash outflows in the quarter.
- Liquidity and obligations: Current assets were $13.85 million and current liabilities were $6.96 million. Total liabilities were $7.50 million, primarily accounts payable and accrued liabilities of $6.90 million and lease liabilities. The filing reports no borrowings or other financial debt.
- Equity: Stockholders’ equity was $7.33 million, down from $15.51 million at December 31, 2022. Common shares outstanding increased from 9.39 million to 9.74 million; 355,235 pre-funded warrants were converted into shares during the quarter. The company also reported 8.24 million outstanding warrants at quarter-end.
Operating margins are not meaningful because the company had no reported revenue. Interest income was $124,000, versus $430 in Q1 2022.
Changes and operating developments
- R&D expense rose by approximately $2.77 million, primarily due to higher clinical trial costs, manufacturing and related costs, personnel, and preclinical activity. Management cited timing of pivotal-trial activity and production sourcing among the drivers.
- Management said the CLOVER-WaM pivotal study’s interim review supported continued enrollment without a dosing change. The company also reported that patient recruitment and enrollment had been materially delayed by COVID-related site-resourcing issues and patient concerns.
- The company received approximately $406,000 in National Cancer Institute grant funding in Q1, recorded as a reduction of R&D expense. The grant supports expansion of the pediatric iopofosine study.
Outlook, risks and notable items
- Runway and going concern: Management believes March 31 cash can fund basic budgeted operations into Q4 2023. Continued execution beyond that point depends on additional financing, a strategic transaction, or other funding. The filing states that substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
- Clinical and execution risks: Cellectar expects ongoing operating losses. Clinical progress, enrollment timelines, trial outcomes, manufacturing and reliance on its sole iopofosine supplier are uncertain. The filing also identifies financing needs and continued Nasdaq listing compliance as risks.
- Pipeline: Iopofosine was being evaluated in the CLOVER-WaM Phase 2 pivotal study, a Phase 2b study in relapsed/refractory multiple myeloma and CNS lymphoma, and a pediatric Phase 1b study. The filing provides no formal financial or earnings guidance.
- Other items: A lawsuit concerning intellectual property was resolved in November 2022; Cellectar obtained an irrevocable, non-exclusive license to the patents at issue. Management reported effective disclosure controls and no significant changes in internal control over financial reporting during the quarter.
Investor verification priorities
- Confirm current cash runway, cash burn, and the status and terms of any subsequent financing or strategic transaction.
- Track CLOVER-WaM enrollment, timing, and eventual efficacy and safety results, including the impact of recruitment delays.
- Review potential dilution from outstanding warrants, options, and future equity financing; confirm the status of the contingent option awards requiring shareholder approval.
- Assess manufacturing and supplier continuity for iopofosine, and monitor Nasdaq listing compliance and the company’s going-concern disclosures.